Estimating the lives that could be saved by expanded access to weight-loss drugs
Pandey A, Ye Y, Wells C, Singer B, Galvani A. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2412872121. PMID: 39405358, PMCID: PMC11513960, DOI: 10.1073/pnas.2412872121.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Body mass index categoriesObesity prevalence dataGlucagon-like peptide-1 receptor agonistsHazard ratio of mortalityRatio of mortalityPublic health impactWeight loss drugsInsurance coverage issuesGastric inhibitory polypeptideHealthcare accessType 2 diabetesUnited StatesPublic health crisisObesity epidemicReceptor agonistsIndex categoriesHazard ratioPrevalence dataInhibitory polypeptidePeptide-1Health impactsNovel treatmentObesityHealth crisisMortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States
Pandey A, Fitzpatrick M, Singer B, Galvani A. Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321494121. PMID: 38648491, PMCID: PMC11066981, DOI: 10.1073/pnas.2321494121.Peer-Reviewed Original ResearchEvaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States. Annals Of Internal Medicine 2024, 177: 609-617. PMID: 38527289, DOI: 10.7326/m23-2451.Peer-Reviewed Original ResearchSARS-CoV-2 vaccination campaignSARS-CoV-2Centers for Disease Control and PreventionDisease Control and PreventionSARS-CoV-2 vaccinesHealth care costsVaccine-acquired immunityFood and Drug AdministrationU.S. Food and Drug AdministrationControl and PreventionNational Institutes of HealthVaccination campaignInfluenza vaccineInitial doseInstitutes of HealthSARS-CoV-2 variantsBooster doseImmune evasionDrug AdministrationUnited StatesNotsew Orm Sands FoundationDoseHealthPopulation immunityNational Institute